GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sana Biotechnology Inc (NAS:SANA) » Definitions » Cash Ratio

Sana Biotechnology (Sana Biotechnology) Cash Ratio : 3.18 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Sana Biotechnology Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Sana Biotechnology's Cash Ratio for the quarter that ended in Dec. 2023 was 3.18.

Sana Biotechnology has a Cash Ratio of 3.18. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Sana Biotechnology's Cash Ratio or its related term are showing as below:

SANA' s Cash Ratio Range Over the Past 10 Years
Min: 3.18   Med: 6.37   Max: 17.16
Current: 3.18

During the past 6 years, Sana Biotechnology's highest Cash Ratio was 17.16. The lowest was 3.18. And the median was 6.37.

SANA's Cash Ratio is ranked better than
51.97% of 1524 companies
in the Biotechnology industry
Industry Median: 2.92 vs SANA: 3.18

Sana Biotechnology Cash Ratio Historical Data

The historical data trend for Sana Biotechnology's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sana Biotechnology Cash Ratio Chart

Sana Biotechnology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 7.19 12.03 5.55 3.80 3.18

Sana Biotechnology Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.80 3.40 2.91 4.03 3.18

Competitive Comparison of Sana Biotechnology's Cash Ratio

For the Biotechnology subindustry, Sana Biotechnology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sana Biotechnology's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sana Biotechnology's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Sana Biotechnology's Cash Ratio falls into.



Sana Biotechnology Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Sana Biotechnology's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=205.195/64.487
=3.18

Sana Biotechnology's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=205.195/64.487
=3.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sana Biotechnology  (NAS:SANA) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Sana Biotechnology Cash Ratio Related Terms

Thank you for viewing the detailed overview of Sana Biotechnology's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sana Biotechnology (Sana Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 400, Seattle, WA, USA, 98102
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. Its operations include identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the company's intellectual property portfolio, raising capital, and providing general and administrative support for these operations.
Executives
Christian Hordo officer: SVP, Chief Business Officer C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Douglas E Williams officer: EVP & President, R&D C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Bernard J Cassidy officer: EVP & General Counsel C/O TUMBLEWEED COMMUNICATIONS CORP, 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
James J. Macdonald officer: See Remarks C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Sunil Agarwal officer: See Remarks 60 LEVERONI COURT, NOVATO CA 94949
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship V Venturelabs Rx Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Venturelabs V Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arch Venture Fund Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Arch Venture Partners Ix Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Sana Biotechnology (Sana Biotechnology) Headlines

From GuruFocus

Sana Biotechnology to Present at May 2023 Investor Conferences

By sperokesalga sperokesalga 05-03-2023

Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023